首页> 外文期刊>Pathology Research and Practice >Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1
【24h】

Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1

机译:具有次要SARCAMATOMAT组分和最新癌症的非小细胞肺癌与编程死亡配体1的高表达有关

获取原文
获取原文并翻译 | 示例
           

摘要

Pleomorphic carcinomas are known to be highly programmed death ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) types. However, the level of PD-L1 expression in lung carcinomas with a minor sarcomatoid component, comprising less than 10 % of the tumor mass, has not been determined yet. We hypothesized that NSCLC with a minor sarcomatoid component is more closely related to pleomorphic carcinomas in terms of PD-L1 expression than to NSCLC types without sarcomatoid features. The surgical resections from 690 lung carcinoma patients were retrospectively analyzed for the presence of PD-L1 by means of immunohistochemistry using the 22C3 PharmDx assay. The tumor proportion score system was applied to quantify the level of PD-L1 expression. Membranous staining present in >= 1 % of tumor cells was chosen as the cut-off to define a positive result for PD-L1 expression. Tumors were allocated into one of four subgroups: "adenocarcinoma", "squamous cell carcinoma", "pleomorphic carcinoma", or "NSCLC with a minor sarcomatoid component". PD-L1 expression in pleomorphic carcinomas (26/32, 81.3 %) and in the subgroup of NSCLC with a minor sarcomatoid component (35/46, 76.1 %) was identified in a comparable proportion of cases. Pleomorphic carcinomas were significantly more often PD-L1 positive than adenocarcinomas (p < 0.001) or squamous cell carcinomas (p = 0.0015). Accordingly, the proportion of PD-L1 expressing NSCLC with a minor sarcomatoid component was significantly higher than that of the adenocarcinoma (p < 0.001) or squamous cell carcinoma (p = 0.002) subgroup. In summary, we identified a presumable new subgroup of highly PD-L1 positive neoplasms within the NSCLC spectrum that is related to pleomorphic carcinomas in terms of PD-L1 expression. Further investigation regarding genetic relation and mechanism of PD-L1 expression in these two NSCLC categories is recommended.
机译:多形性癌是已知的高度程序化死亡配体1(PD-L1)阳性的非小细胞肺癌(NSCLC)类型。然而,PD-L1在含有少量肉瘤样成分的肺癌中的表达水平尚未确定,肉瘤样成分占肿瘤重量的比例不到10%。我们假设,在PD-L1表达方面,具有少量肉瘤样成分的NSCLC与多形性癌的关系比不具有肉瘤样特征的NSCLC更密切。对690例肺癌患者的手术切除进行回顾性分析,通过使用22C3 PharmDx分析的免疫组织化学方法检测PD-L1的存在。应用肿瘤比例评分系统量化PD-L1表达水平。选择>=1%的肿瘤细胞中存在的膜染色作为分界点,以确定PD-L1表达的阳性结果。肿瘤被分为四个亚组:“腺癌”、“鳞状细胞癌”、“多形性癌”或“含有少量肉瘤样成分的NSCLC”。PD-L1在多形性癌(26/32,81.3%)和非小细胞肺癌亚组(35/46,76.1%)中的表达在相当比例的病例中被确定。多形性癌PD-L1阳性率明显高于腺癌(p<0.001)或鳞状细胞癌(p=0.0015)。因此,PD-L1表达的NSCLC中含有少量肉瘤样成分的比例显著高于腺癌(p<0.001)或鳞状细胞癌(p=0.002)亚组。总之,我们在NSCLC谱中发现了一个可能的新的高PD-L1阳性肿瘤亚群,该亚群与PD-L1表达的多形性癌有关。建议进一步研究这两类NSCLC中PD-L1表达的遗传关系和机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号